FindTrial
Sign In

Clinical effect of low-dose ropivacaine hydrochloride combined with sufentanil epidural anesthesia in painless delivery of primiparae

Clinical effect of low-dose ropivacaine hydrochloride combined with sufentanil epidural anesthesia in painless delivery of primiparae

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096274
Enrollment
Unknown
Registered
2025-01-21
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain-free delivery

Interventions

L1 group: 0.08% ropivacaine+0.5g/ml sufentanil, 200 ml in total.
L2 group: 0.1% ropivacaine+0.5g/ml sufentanil, 200 ml in total.
L3 group:0.2% ropivacaine+0.5g/ml sufentanil, 200 ml in total.

Sponsors

Peking University Third Hospital Yanqing Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Primipara, aged 20-40 years old, ASA grade I-II, pregnancy =36 weeks, singleton head position, no obstetric, gynecological and pregnancy complications.

Exclusion criteria

Exclusion criteria: There were no contraindications to vaginal delivery and spinal anesthesia, and pathological obstetrics, recent use of analgesics and neuropsychiatric diseases were excluded.

Design outcomes

Primary

MeasureTime frame
VAS score;General information of pregnant women;Cervical hardness;Soft birth canal basin muscle strength;—

Secondary

MeasureTime frame
Duration of labor;Postpartum blood loss;The amount of oxytocin used;Apgar score;—

Countries

China

Contacts

Public ContactLi Na

Peking University Third Hospital Yanqing Hospital

13832374400@139.com+86 138 3237 4400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026